Home | Donate | Careers | Contact Us | Physicians | 1.888.STJOES1
About St. Joseph's
Home - News Media Center - News Releases

St. Joseph’s is First in Upstate New York to Adopt New Peripheral Artery Disease Treatment

SYRACUSE, N.Y. ­– St. Joseph’s Hospital Health Center is the first facility in Upstate New York to utilize Zilver PTX, a treatment for peripheral artery disease (PAD). The treatment is the first of its kind approved for use in the legs and gives patients a reduced chance of needing a repeat procedure.

“The interventional cardiologists at St. Joseph’s quickly embraced the opportunity to use the new treatment to help a patient,” said Ayman Iskander, MD, FACC, FSCAI, an interventional cardiologist at St. Joseph’s. “As soon as it became available, we immediately used Zilver PTX to treat a patient’s superficial femoral artery.”

Zilver PTX is the first peripheral vascular device to combine the mechanical support of stenting with targeted delivery of paclitaxel, a cell growth-limiting drug proven to reduce post-procedural blockages. To use it, physicians gain arterial access through the groin and guide a ZPTX stent to the narrowed artery with a catheter. The stent expands to keep the artery open and the paclitaxel, which coats the stent, helps prevent the artery from re-narrowing over time. By coating the stent without the use of a polymer, Zilver PTX eliminates risks that often arise directly from polymers.  

A clinical trial showed that seven out of 10 patients treated with ZPTX still had an open artery after two years compared to just three out of 10 patients treated with angioplasty alone. The rate of repeat interventions needed to reopen the artery in PTX patients was more than half the rate of patients with bare metal stents.

PAD is a chronic, progressive circulatory disease affecting eight to 12 million Americans every year. Patients suffer from plaque buildup in their arteries, which limits blood flow. It typically affects arteries in the legs, but can also affect blood flow to the head, arms, kidneys and gastrointestinal tract.  A silent disease, it only presents symptoms in one quarter of those affected. Patients are often not diagnosed until their condition has progressed to a severe stage. Current treatments for PAD include lifestyle changes, medication, exercise, angioplasty, bare metal stenting and bypass surgery.

To date, Dr. Iskander has completed five procedures with great success.

St. Joseph’s Hospital Health Center is a non-profit, 431-bed hospital and health care system in Syracuse, New York, providing services to patients in 16 counties in Central New York State. Through prevention programs and the latest diagnostic treatment procedures, St. Joseph's works with patients to achieve optimum long-term health. A 15-time winner of the National Research Corporation Consumer Choice award, St. Joseph’s is affiliated with Franciscan Companies and sponsored by the Sisters of St. Francis.